Search
InnoCare Pharma's BCL2 Inhibitor Gains FDA Approval for U.S. Clinical Trial
1 week ago /
Read about 0 minute
Author：小编
InnoCare Pharma's proprietary, orally administered, high-selectivity BCL2 inhibitor, mesutoclax (ICP-248), has secured approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials. This novel compound, when combined with azacitidine, aims to treat myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Mesutoclax exerts its anti-tumor effects by selectively targeting BCL2, thereby restoring the natural process of programmed cell death in tumor cells.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
